Nuclear-Based Labeling of Cellular Immunotherapies: A Simple Protocol for Preclinical Use.
Alessia Volpe1, Serge K Lyashchenko1, Vladimir Ponomarev2,3,4
1Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Molecular Imaging and Biology
|July 3, 2024
Summary
Nuclear imaging enables tracking of cell immunotherapies for preclinical development. This protocol details labeling methods to make cell therapies traceable in vivo, aiding research and FDA approval.
Area of Science:
- Immunotherapy
- Nuclear Imaging
- Preclinical Research
Background:
- Cell-based immunotherapies are crucial for cancer treatment.
- Nuclear imaging is vital for tracking these therapies during preclinical development.
- Understanding therapy mechanisms and limitations supports clinical translation and FDA approval.
Purpose of the Study:
- To provide a comprehensive protocol for labeling cell-based immunotherapies.
- To enable in vivo traceability of candidate cell therapies using nuclear imaging.
- To support researchers in preclinical development and expedite regulatory approval.
Main Methods:
- Detailed description of labeling methodologies for cell therapies.
- Practical procedures for rendering cell therapies traceable in vivo.
- Guidance on incorporating nuclear imaging techniques into research workflows.
Main Results:
- A ready-to-use protocol for in vivo cell therapy tracking is presented.
- The protocol is designed for researchers across various career stages and disciplines.
- Facilitates understanding of cell therapy behavior and efficacy in preclinical models.
Conclusions:
- This protocol standardizes nuclear imaging-based tracking of cell immunotherapies.
- It supports the preclinical evaluation of novel cell therapies.
- Accelerates the translation of cell-based immunotherapies to clinical application and FDA approval.
